Why This Dismissed Investment Is Now a Promising Long-Term Gem

Bausch Health Companies (TSX:BHC)(NYSE:BHC) remains one of the most misunderstood companies on the market today.

| More on:

Image source: Getty Images.

There are few stocks on the market today that are as loathed by investors as Bausch Health Companies (TSX:BHC)(NYSE:BHC). For those investors that need a quick recap, several years ago, under a different name, Bausch’s stock, which was on a cheap-loan-fueled ascension, finally crashed and came tumbling down. The ensuing result was a loss of over 90% in stock value, and Bausch was left with a broken business model, staggering debt, and a slew of court cases.

One of the first reactions by investors who realize that Bausch is the new name of the former entity known as Valeant is overwhelmingly negative. I can appreciate that, particularly as, at the time of its collapse, Valeant was a darling of the market with a market cap that was greater than some of Canada’s big banks.

That being said, today’s Bausch is very different than Valeant — so much that it really doesn’t do justice to mention them together in the same context.

Don’t hate Valeant’s successor: This is a very different company

The two core areas where Bausch has excelled over its prior incarnation have to do with managing its substantial (yet shrinking) debt and how the company plans to continue growing over the next decade.

While the $23 billion in debt that Bausch carries is a lot, it is significantly lower than the more than $30 billion that the company had at the time of the stock collapsing. Bausch sold off non-core and underperforming assets from its massive portfolio to fund that aggressive repayment schedule, and as a result, the company has few, if any, repayments due before 2021.

This has allowed Bausch to turn towards growth and revenue generation. Progress has been slow, with the company posting a revenue gain of just over 1% during the first half of 2019. That being said, there are some stars within Bausch’s portfolio that could become significant growth drivers for the company over the next decade.

I say significant because that’s exactly how Bausch refers to those opportunities. A slew of products dubbed the “Significant Seven” by Bausch is set to bring in a billion in revenue. Some of the Significant Seven have already made inroads to reaching that goal, such as Xifaxan, which saw a 21% jump in revenue when compared to the previous year.

In short, a steadily improving balance sheet and an increasingly popular and successful line of products are set to help propel Bausch to new highs over the long term. Bausch has already updated its guidance in 2019 to reflect that potential, with the company now forecasting revenue for 2019 to fall between $8.4 billion and $8.6 billion.

Bausch is set to provide updated financials for the third quarter in a few weeks. In the second quarter, Bausch saw revenues top 3% over the prior year to $2,152 million while also generating $339 million in cash from operations.

Should you buy Bausch?

Bausch currently trades at just below $30 and is not without risk. That being said, Bausch appeals to investors looking to diversify their portfolio with an investment that will provide growth over the long term.

In other words, if you can tolerate some risk, buy it and hold it.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Demetris Afxentiou has no position in any of the stocks mentioned. The Motley Fool owns shares of Bausch Health Companies.

More on Investing

Business man on stock market financial trade indicator background.
Tech Stocks

1 Growth Stock Down 50 Percent to Buy Right Now

There are plenty of growth stocks in the market worth considering, but Shopify (TSX:SHOP) looks like one of the best…

Read more »

You Should Know This
Dividend Stocks

How to Convert a $300 Monthly Investment Into $338 in Monthly Income

If you want a certain amount in monthly passive income, invest a similar amount today and leave the rest to…

Read more »

Increasing yield
Dividend Stocks

3 Income Stocks With Big Yields to Consider in April 2024

If you haven’t yet made your March investments, here are three income stocks to buy the dip and lock in…

Read more »

Senior Man Sitting On Sofa At Home With Pet Labrador Dog
Dividend Stocks

RRSP Investors: Don’t Miss Out on This Contribution Hack!

This hack has so many benefits for you -- not just when you put it in your RRSP but for…

Read more »

edit Sale sign, value, discount
Stocks for Beginners

These 3 Growth Stocks Are on Sale and Set to Surge

Some growth stocks are on sale right now that offer massive long-term potential for investors. Here's a trio to consider…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Young woman sat at laptop by a window
Dividend Stocks

3 Dividend Stocks Everyone Should Own for the Long Haul

For investors looking for top-tier dividend stocks to buy and hold for the long term, here are three of my…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

Passive Income: 2 Safe Dividend Stocks to Own for the Next 10 Years

Dividend stocks such as Manulife and Fortis can help you generate a stable and recurring passive-income stream.

Read more »